73 results
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
. On March 26, 2019, we and Enlivex Therapeutics Ltd. (n/k/a Enlivex Therapeutics R&D Ltd., “Enlivex R&D”), consummated a merger transaction whereby Enlivex R … &D merged with one of our wholly owned subsidiaries, with Enlivex R&D as the surviving entity in the merger. Upon consummation of the merger, we
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
, responsible for the global clinical development of sorafenib (Nexavar ® ) at Bayer. Former CEO of PROLOR Biotech. Founding team and Director of R&D
6-K
EX-99.1
a84upe5
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
l5h212me25y29hhw4y
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
rvis 42k5dsr9b7w
31 Mar 23
Report of Foreign Private Issuer
4:30pm
424B5
5xx 91qn5ntd
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
mg2qxkiyo0q0hgxx
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.1
xco8qhp4nfdekf8vkc
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
d5p09f5 a9co
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
aqi 7zg7u8t2sx7v
24 Aug 22
Report of Foreign Private Issuer
8:05am
6-K
EX-99.2
s8e9opc
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.3
n8xr2o
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
srm2u84h9r5meq6dz
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
crlserfv57ca02bguss
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
ycm a51swvgci
27 May 22
Condensed Consolidated Financial Statements
4:39pm